HIV vaccine: Hopes and hurdles

Drug Discovery Today

Volumn 16, Issue 21-22, 2011, Pages 948-956

  Chhatbar, Chintan ^a   Mishra, Ritu ^a   Kumar, Ashish ^b   Singh, Sunit Kumar ^a  

^a CENTRE FOR CELLULAR AND MOLECULAR BIOLOGY   (India)

^b KING GEORGE'S MEDICAL UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALUMINUM POTASSIUM SULFATE; DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LIPID A; LIPOSOME; MIFAMURTIDE; NEUTRALIZING ANTIBODY; RECOMBINANT GLYCOPROTEIN GP 120; VIRUS VECTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CLINICAL TRIAL (TOPIC); CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; ELECTROPORATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; NONHUMAN; REVIEW; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS REPLICATION;

AIDS VACCINES; DRUG DISCOVERY; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS;

EID: 80255137044     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2011.08.013     Document Type: Review

References (113)

1. M.L. Gougeon To kill or be killed: how HIV exhausts the immune system Cell Death Differ. 12 Suppl. 1 2005 845 854
2. D.C. Douek HIV preferentially infects HIV-specific CD4+ T cells Nature 417 2002 95 98 (Pubitemid 34498823)
3. S. Li Persistent CCR5 utilization and enhanced macrophage tropism by primary blood human immunodeficiency virus type 1 isolates from advanced stages of disease and comparison to tissue-derived isolates J. Virol. 73 1999 9741 9755
4. T.H. Finkel Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes Nat. Med. 1 1995 129 134
5. U. Abdel-Motal Increased immunogenicity of human immunodeficiency virus gp120 engineered to express Galalpha1-3Galbeta1-4GlcNAc-R epitopes J. Virol. 80 2006 6943 6951 (Pubitemid 44025193)
6. S. Bellino Parallel conduction of the Phase I preventive and therapeutic trials based on the Tat vaccine candidate Rev. Recent Clin. Trials 4 2009 195 204
7. D.M. Asmuth Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens J. Infect. Dis. 201 2010 132 141
8. J.B. Sacha Gag-specific CD8+ T lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression J. Immunol. 178 2007 2746 2754 (Pubitemid 46333151)
9. R.C. Pandey HIV-1 Vpr: a closer look at the multifunctional protein from the structural perspective Curr. HIV Res. 7 2009 114 128
10. B. Schrofelbauer New insights into the role of Vif in HIV-1 replication AIDS Rev. 6 2004 34 39 (Pubitemid 38607539)
11. V. Ayyavoo Immunogenicity of a novel DNA vaccine cassette expressing multiple human immunodeficiency virus (HIV-1) accessory genes AIDS 14 2000 1 9 (Pubitemid 30072072)
12. L.J. Patterson Potent, persistent cellular immune responses elicited by sequential immunization of rhesus macaques with Ad5 host range mutant recombinants encoding SIV Rev and SIV Nef DNA Cell Biol. 21 2002 627 635 (Pubitemid 35155685)
13. M.R. Reynolds Macaques vaccinated with live-attenuated SIV control replication of heterologous virus J. Exp. Med. 205 2008 2537 2550
14. S.J. Draper, and J.L. Heeney Viruses as vaccine vectors for infectious diseases and cancer Nat. Rev. Microbiol. 8 2010 62 73
15. S. Rerks-Ngarm Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand N. Engl. J. Med. 361 2009 2209 2220
16. J.F. Scheid Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals Nature 458 2009 636 640
17. M. Schiavone Perspectives for a protective HIV-1 vaccine Adv. Pharmacol. 56 2008 423 452
18. K.K. Van Rompay Immunogenicity of viral vector, prime-boost SIV vaccine regimens in infant rhesus macaques: attenuated vesicular stomatitis virus (VSV) and modified vaccinia Ankara (MVA) recombinant SIV vaccines compared to live-attenuated SIV Vaccine 28 2010 1481 1492
19. M.J. McElrath HIV-1 vaccine-induced immunity in the test-of-concept step study: a case-cohort analysis Lancet 372 2008 1894 1905
20. E.L. Cooney Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein Proc. Natl. Acad. Sci. U. S. A. 90 1993 1882 1886 (Pubitemid 23069961)
21. A. Harari An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses J. Exp. Med. 205 2008 63 77 (Pubitemid 351185716)
22. S. Edupuganti Cytotoxic T-lymphocyte responses to canarypox vector-based HIV vaccines in HIV-seronegative individuals: a meta-analysis of published studies HIV Clin. Trials 5 2004 259 268 (Pubitemid 39545398)
23. A. Benlahrech Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1 Proc. Natl. Acad. Sci. U. S. A. 106 2009 19940 19945
24. G. Gray Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine Curr. Opin. HIV AIDS 5 2010 357 361
25. D.H. Barouch Novel adenovirus vector-based vaccines for HIV-1 Curr. Opin. HIV AIDS 5 2010 386 390
26. P. Abbink Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D J. Virol. 81 2007 4654 4663 (Pubitemid 46668663)
27. D.M. Roberts Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity Nature 441 2006 239 243
28. S.N. Waddington Adenovirus serotype 5 hexon mediates liver gene transfer Cell 132 2008 397 409 (Pubitemid 351200513)
29. K. Lore Myeloid and plasmacytoid dendritic cells are susceptible to recombinant adenovirus vectors and stimulate polyfunctional memory T cell responses J. Immunol. 179 2007 1721 1729
30. H. Kibuuka A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-uninfected East Africans (RV 172) J. Infect. Dis. 201 2010 600 607
31. D.C. Tang Genetic immunization is a simple method for eliciting an immune response Nature 356 1992 152 154
32. J.L. Brandsma Therapeutic vaccination of rabbits with a ubiquitin-fused papillomavirus E1, E2, E6 and E7 DNA vaccine Vaccine 25 2007 6158 6163 (Pubitemid 47088042)
33. A.T. Catanzaro Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine Vaccine 25 2007 4085 4092 (Pubitemid 46616987)
34. R.R. MacGregor T-cell responses induced in normal volunteers immunized with a DNA-based vaccine containing HIV-1 env and rev AIDS 16 2002 2137 2143 (Pubitemid 35387267)
35. J.M. Vuola Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers J. Immunol. 174 2005 449 455 (Pubitemid 40007434)
36. H.L. Robinson HIV/AIDS vaccines: 2007 Clin. Pharmacol. Ther. 82 2007 686 693 (Pubitemid 350114827)
37. G.T. Jennings, and M.F. Bachmann The coming of age of virus-like particle vaccines Biol. Chem. 389 2008 521 536 (Pubitemid 351874198)
38. S.P. McBurney Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes Virology 358 2007 334 346 (Pubitemid 46138113)
39. Z. Hunter Induction of mucosal and systemic antibody responses against the HIV coreceptor CCR5 upon intramuscular immunization and aerosol delivery of a virus-like particle based vaccine Vaccine 28 2009 403 414
40. P.L. Moore Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1 J. Virol. 80 2006 2515 2528 (Pubitemid 43271557)
41. E.T. Crooks A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120 Virology 366 2007 245 262 (Pubitemid 47393683)
42. P. Poignard Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies J. Virol. 77 2003 353 365 (Pubitemid 36004975)
43. X. Jin Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques J. Exp. Med. 189 1999 991 998 (Pubitemid 29149355)
44. K.J. Metzner Effects of in vivo CD8(+) T cell depletion on virus replication in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine J. Exp. Med. 191 2000 1921 1931 (Pubitemid 30390354)
45. J.E. Schmitz Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes Science 283 1999 857 860
46. J.B. Sacha Gag- and Nef-specific CD4+ T cells recognize and inhibit SIV replication in infected macrophages early after infection Proc. Natl. Acad. Sci. U. S. A. 106 2009 9791 9796
47. W.M. Cohen Scanning the HIV genome for CD4+ T cell epitopes restricted to HLA-DP4, the most prevalent HLA class II molecule J. Immunol. 176 2006 5401 5408
48. D.E. Kaufmann Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides J. Virol. 78 2004 4463 4477 (Pubitemid 38501066)
49. M. Carrington HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage Science 283 1999 1748 1752
50. M.I. Johnston, and A.S. Fauci An HIV vaccine - evolving concepts N. Engl. J. Med. 356 2007 2073 2081 (Pubitemid 46789897)
51. S. Vasan Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine PLoS One 5 2010 e8617
52. B. Moss Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety Proc. Natl. Acad. Sci. U. S. A. 93 1996 11341 11348 (Pubitemid 26347123)
53. L.E. Harrington Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope J. Virol. 76 2002 3329 3337 (Pubitemid 34224535)
54. J. Schneider Induction of CD8+ T cells using heterologous prime-boost immunisation strategies Immunol. Rev. 170 1999 29 38 (Pubitemid 29490742)
55. B. Chen Structure of an unliganded simian immunodeficiency virus gp120 core Nature 433 2005 834 841 (Pubitemid 40314887)
56. P.D. Kwong Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody Nature 393 1998 648 659 (Pubitemid 28289647)
57. S.M. Alam Role of HIV membrane in neutralization by two broadly neutralizing antibodies Proc. Natl. Acad. Sci. U. S. A. 106 2009 20234 20239
58. X. Wu Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1 Science 329 2010 856 861
59. D.R. Burton Antibody vs. HIV in a clash of evolutionary titans Proc. Natl. Acad. Sci. U. S. A. 102 2005 14943 14948 (Pubitemid 41513316)
60. M.J. McElrath, and B.F. Haynes Induction of immunity to human immunodeficiency virus type-1 by vaccination Immunity 33 2010 542 554
61. M.J. McElrath A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation Group AIDS Res. Hum. Retroviruses 16 2000 907 919 (Pubitemid 30399610)
62. M.J. McElrath Selection of potent immunological adjuvants for vaccine construction Semin. Cancer Biol. 6 1995 375 385
63. J.R. Mascola, and D.C. Montefiori The role of antibodies in HIV vaccines Ann. Rev. Immunol. 28 2010 413 444
64. F. Gao Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity Expert Rev. Vaccines 3 Suppl. 4 2004 161 168
65. F. Gao Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein J. Virol. 79 2005 1154 1163 (Pubitemid 40053898)
66. B. Ensoli Criteria for selection of HIV vaccine candidates - general principles Microbes Infect. 7 2005 1433 1435 (Pubitemid 41653489)
67. L. Chen Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120 Science 326 2009 1123 1127
68. D.D. Richman Rapid evolution of the neutralizing antibody response to HIV type 1 infection Proc. Natl. Acad. Sci. U. S. A. 100 2003 4144 4149 (Pubitemid 36418171)
69. K. Smith Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen Nat. Protoc. 4 2009 372 384
70. A.J. McMichael The immune response during acute HIV-1 infection: clues for vaccine development Nat. Rev. Immunol. 10 2010 11 23
71. K.L. Davis High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination Virology 387 2009 414 426
72. T.J. Palker A conserved region at the COOH terminus of human immunodeficiency virus gp120 envelope protein contains an immunodominant epitope Proc. Natl. Acad. Sci. U. S. A. 84 1987 2479 2483 (Pubitemid 17075889)
73. J.W. Gnann Jr. Diagnosis of AIDS by using a 12-amino acid peptide representing an immunodominant epitope of the human immunodeficiency virus J. Infect. Dis. 156 1987 261 267 (Pubitemid 17098187)
74. F. Hladik, and T.J. Hope HIV infection of the genital mucosa in women Curr. HIV/AIDS Rep. 6 2009 20 28
75. R.H. Florese Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines J. Immunol. 182 2009 3718 3727
76. A.L. DeVico, and R.C. Gallo Control of HIV-1 infection by soluble factors of the immune response Nat. Rev. Microbiol. 2 2004 401 413 (Pubitemid 39490119)
77. C.N. Scanlan The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1 - >2 mannose residues on the outer face of gp120 J. Virol. 76 2002 7306 7321
78. G. Stiegler A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1 AIDS Res. Hum. Retroviruses 17 2001 1757 1765 (Pubitemid 34114213)
79. T. Muster A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1 J. Virol. 67 1993 6642 6647 (Pubitemid 23309131)
80. D.R. Burton Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody Science 266 1994 1024 1027 (Pubitemid 24373715)
81. A.J. Hessell Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L J. Virol. 84 2010 1302 1313
82. M.B. Zwick Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1 J. Virol. 79 2005 1252 1261 (Pubitemid 40053907)
83. L. Stamatatos Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat. Med. 15 2009 866 870
84. B.F. Haynes Is developing an HIV-1 vaccine possible? Curr. Opin. HIV AIDS 5 2010 362 367
85. X. Shen In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth J. Virol. 83 2009 3617 3625
86. D.C. Montefiori, and J.R. Mascola Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need? Curr. Opin. HIV AIDS 4 2009 347 351
87. B.F. Haynes Antibody polyspecificity and neutralization of HIV-1: a hypothesis Hum. Antibodies 14 2005 59 67
88. J.M. Binley Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization J. Virol. 84 2010 5637 5655
89. G. Frey A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies Proc. Natl. Acad. Sci. U. S. A. 105 2008 3739 3744 (Pubitemid 351723468)
90. W.R. Schief Challenges for structure-based HIV vaccine design Curr. Opin. HIV AIDS 4 2009 431 440
91. P.D. Kwong HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites Nature 420 2002 678 682 (Pubitemid 36764500)
92. R.D. Astronomo A glycoconjugate antigen based on the recognition motif of a broadly neutralizing human immunodeficiency virus antibody, 2G12, is immunogenic but elicits antibodies unable to bind to the self glycans of gp120 J. Virol. 82 2008 6359 6368 (Pubitemid 351875114)
93. L. Verkoczy Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance Proc. Natl. Acad. Sci. U. S. A. 107 2010 181 186
94. N.M. Flynn Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection J. Infect. Dis. 191 2005 654 665
95. P. Pitisuttithum Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1 J. Acquir. Immune Defic. Syndr. 37 2004 1160 1165 (Pubitemid 39166651)
96. N.L. Letvin Virology. Moving forward in HIV vaccine development Science 326 2009 1196 1198
97. S. Mehandru Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract J. Exp. Med. 200 2004 761 770 (Pubitemid 39299462)
98. A.J. McMichael, and S.L. Rowland-Jones Cellular immune responses to HIV Nature 410 2001 980 987 (Pubitemid 32335849)
99. N.A. Hutnick Adenovirus-specific human T cells are pervasive, polyfunctional, and cross-reactive Vaccine 28 2010 1932 1941
100. L. Trautmann Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction Nat. Med. 12 2006 1198 1202 (Pubitemid 44527357)
101. U. Malhotra Role for HLA class II molecules in HIV-1 suppression and cellular immunity following antiretroviral treatment J. Clin. Invest. 107 2001 505 517 (Pubitemid 32167997)
102. B.K. Brown Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models Virology 375 2008 529 538
103. M.J. van Gils High prevalence of neutralizing activity against multiple unrelated human immunodeficiency virus type 1 (HIV-1) subtype B variants in sera from HIV-1 subtype B-infected individuals: evidence for subtype-specific rather than strain-specific neutralizing activity J. Gen. Virol. 91 Part 1 2010 250 258
104. M.D. Simek Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm J. Virol. 83 2009 7337 7348
105. C. Harro Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adults Clin. Vaccine Immunol. 16 2009 1285 1292
106. J. Holmgren, and C. Czerkinsky Mucosal immunity and vaccines Nat. Med. 11 Suppl. 4 2005 45 53
107. S.W. Barnett Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope AIDS 22 2008 339 348
108. C.R. Rinaldo Dendritic cell-based human immunodeficiency virus vaccine J. Intern. Med. 265 2009 138 158
109. C. Trumpfheller The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine Proc. Natl. Acad. Sci. U. S. A. 105 2008 2574 2579 (Pubitemid 351520555)
110. E.R. Van Gulck Efficient stimulation of HIV-1-specific T cells using dendritic cells electroporated with mRNA encoding autologous HIV-1 Gag and Env proteins Blood 107 2006 1818 1827 (Pubitemid 43289359)
111. D.H. Barouch Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys Nat. Med. 16 2010 319 323
112. S. Santra Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys Nat. Med. 16 2010 324 328
113. W. Fischer Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants Nat. Med. 13 2007 100 106 (Pubitemid 46067393)